Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Prognostic models are lacking for patients with recurrent hepatocellular carcinoma (HCC) following surgical resection. This study devised and validated a new hepatoma arterial-embolization prognostic (HAP) score optimized for use in patients undergoing treatment with transarterial chemoembolization (TACE) for recurrence subsequent to surgical resection of HCC. Methods: Training cohort (n=424) and validation cohort (n=350) patients with recurrent HCC after resection treated with TACE between 2003 and 2016 were enrolled. Cox regression and area under the receiver operating characteristic curve (AUC) analyses were used to identify risk factors for survival and to calculate the predictive performance of risk scores, respectively. Results: The median age of the study population was 59.2 years. α-Fetoprotein >400 ng/mL (hazard ratio [HR]=1.815), serum albumin ≤3.5 g/dL (HR=1.966), tumor number ≥2 (HR=1.425), tumor size >5 cm at resection or recurrence (HR=1.356), segmental portal vein invasion at resection or recurrence (HR=2.032), and time from resection to recurrence ≤1 years (HR=1.849) independently predicted survival (all p<0.05). The postoperative HAP (pHAP) model based on the rounded HRs of these variables showed an AUC of 0.723 for predicting survival at 3 years, which was significantly higher than AUCs of other HAP-based models, including HAP, modified HAP, and modified HAP-II scores (0.578-0.621) (all p<0.05). The accuracy of pHAP was maintained in the entire cohort (n=774; AUC=0.776 at 3 years). Conclusions: A new pHAP score optimized for patients treated with TACE due to recurrent HCC after resection showed acceptable accuracy and was externally validated. Further studies of means by which to select treatment options other than TACE for high-risk patients according to pHAP scores are warranted.
Abstract
Background/Aims: Prognostic models are lacking for patients with recurrent hepatocellular carcinoma (HCC) following surgical resection. This study devised and validated a new hepatoma arterial-embolization prognostic (HAP) score optimized for use in patients undergoing treatment with transarterial chemoembolization (TACE) for recurrence subsequent to surgical resection of HCC. Methods: Training cohort (n=424) and validation cohort (n=350) patients with recurrent HCC after resection treated with TACE between 2003 and 2016 were enrolled. Cox regression and area under the receiver operating characteristic curve (AUC) analyses were used to identify risk factors for survival and to calculate the predictive performance of risk scores, respectively. Results: The median age of the study population was 59.2 years. α-Fetoprotein >400 ng/mL (hazard ratio [HR]=1.815), serum albumin ≤3.5 g/dL (HR=1.966), tumor number ≥2 (HR=1.425), tumor size >5 cm at resection or recurrence (HR=1.356), segmental portal vein invasion at resection or recurrence (HR=2.032), and time from resection to recurrence ≤1 years (HR=1.849) independently predicted survival (all p<0.05). The postoperative HAP (pHAP) model based on the rounded HRs of these variables showed an AUC of 0.723 for predicting survival at 3 years, which was significantly higher than AUCs of other HAP-based models, including HAP, modified HAP, and modified HAP-II scores (0.578-0.621) (all p<0.05). The accuracy of pHAP was maintained in the entire cohort (n=774; AUC=0.776 at 3 years). Conclusions: A new pHAP score optimized for patients treated with TACE due to recurrent HCC after resection showed acceptable accuracy and was externally validated. Further studies of means by which to select treatment options other than TACE for high-risk patients according to pHAP scores are warranted.
참고문헌 (30)
- El-Serag HB, "Epidemiology of viral hepatitis and hepatocellular carcinoma", Gastroenterology, 142, pp.1264~1273 (2012)
- Yuen MF, "Early detection of hepatocellular carcinoma increases the chance of treatment : Hong Kong experience", Hepatology, 31, pp.330~335 (2000)
- 이정민, "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis", Clinical and Molecular Hepatology, 22(1), pp.160~167 (2016), 대한간학회
- 김준영, "Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma", Clinical and Molecular Hepatology, 22(2), pp.250~258 (2016), 대한간학회
- Tung-Ping Poon R, "Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma", Ann Surg, 232, pp.10~24 (2000)
- Kim BK, "Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma", J Hepatol, 62, pp.1304~1310 (2015)
- Park MS, "Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis", Cancer Chemother Pharmacol, 71, pp.165~173 (2013)
- Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
- Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Jung KS, "Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma : development and validation of a predictive model", PLoS One, 9, pp.e99167~ (2014)
- Kadalayil L, "A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer", Ann Oncol, 24, pp.2565~2570 (2013)
- Pinato DJ, "Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification", Clin Gastroenterol Hepatol, 13, pp.1204~1208 (2015)
- Park Y, "Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score", Liver Int, 36, pp.100~107 (2016)
- Korean Liver Cancer Study Group, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Forner A, "Current strategy for staging and treatment : the BCLC update and future prospects", Semin Liver Dis, 30, pp.61~74 (2010)
- Kim BK, "Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation", Eur J Cancer, 49, pp.826~834 (2013)
- Forner A, "Treatment of intermediate-stage hepatocellular carcinoma", Nat Rev Clin Oncol, 11, pp.525~535 (2014)
- Marelli L, "Transarterial therapy for hepatocellular carcinoma : which technique is more effective? A systematic review of cohort and randomized studies", Cardiovasc Intervent Radiol, 30, pp.6~25 (2007)
- Raoul JL, "Evolving strategies for the management of intermediate-stage hepatocellular carcinoma : available evidence and expert opinion on the use of transarterial chemoembolization", Cancer Treat Rev, 37, pp.212~220 (2011)
- Pinato DJ, "Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma : a multi-center comparative study", Oncotarget, 7, pp.44705~44718 (2016)
- Zhao Y, "Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis : a systematic review", Asia Pac J Clin Oncol, 9, pp.357~364 (2013)
- Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients", Gastroenterology, 131, pp.461~469 (2006)
- Georgiades CS, "Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization", J Vasc Interv Radiol, 17, pp.1619~1624 (2006)
- Luo J, "Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis : a prospective comparative study", Ann Surg Oncol, 18, pp.413~420 (2011)
- Park JH, "Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma", Am J Surg, 192, pp.29~33 (2006)
- Kim BK, "Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization : development of a prediction model", Liver Int, 36, pp.92~99 (2016)
- Adhoute X, "Retreatment with TACE : the ABCR SCORE, an aid to the decision-making process", J Hepatol, 62, pp.855~862 (2015)
- Sieghart W, "The ART of decision making : retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma", Hepatology, 57, pp.2261~2273 (2013)